Immunovant Files 8-K on Shareholder Vote Matters
Ticker: IMVT · Form: 8-K · Filed: Aug 13, 2024 · CIK: 1764013
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, 8-k
TL;DR
Immunovant filed an 8-K on Aug 12th regarding shareholder votes. Nothing major disclosed yet.
AI Summary
Immunovant, Inc. filed an 8-K on August 13, 2024, reporting on matters submitted to a vote of security holders on August 12, 2024. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 320 West 37th Street, New York, NY 10018. The company was formerly known as Health Sciences Acquisitions Corp. until January 8, 2019.
Why It Matters
This filing provides official updates on corporate governance and shareholder decisions, which are crucial for investors to understand the company's direction and management.
Risk Assessment
Risk Level: low — The filing is procedural, reporting on a shareholder vote without disclosing new material financial or operational information.
Key Players & Entities
- Immunovant, Inc. (company) — Registrant
- August 12, 2024 (date) — Date of earliest event reported
- August 13, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 320 West 37th Street, New York, NY 10018 (address) — Principal executive offices
- Health Sciences Acquisitions Corp. (company) — Former company name
- January 8, 2019 (date) — Date of name change
FAQ
What specific matters were submitted to a vote of Immunovant's security holders on August 12, 2024?
The filing states that matters were submitted to a vote of security holders on August 12, 2024, but does not specify the exact nature of these matters in the provided text.
When was Immunovant, Inc. incorporated?
Immunovant, Inc. was incorporated in Delaware.
What is Immunovant's principal executive office address?
Immunovant's principal executive offices are located at 320 West 37th Street, New York, NY 10018.
What was Immunovant's former company name?
Immunovant, Inc. was formerly known as Health Sciences Acquisitions Corp.
On what date did the company change its name from Health Sciences Acquisitions Corp.?
The company changed its name from Health Sciences Acquisitions Corp. on January 8, 2019.
Filing Stats: 665 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-08-13 16:12:19
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMVT The Nasdaq Sto
Filing Documents
- imvt-20240812.htm (8-K) — 36KB
- 0001764013-24-000150.txt ( ) — 157KB
- imvt-20240812.xsd (EX-101.SCH) — 2KB
- imvt-20240812_lab.xml (EX-101.LAB) — 21KB
- imvt-20240812_pre.xml (EX-101.PRE) — 12KB
- imvt-20240812_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On August 12, 2024, Immunovant, Inc. ("Immunovant") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). There were 138,261,565 shares of common stock and Series A preferred stock represented at the Annual Meeting by valid proxies or voted at the Annual Meeting, which was approximately 95% of the shares of common stock and Series A preferred stock entitled to vote at the Annual Meeting. At the Annual Meeting, Immunovant's stockholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in Immunovant's definitive proxy statement for the Annual Meeting (the "Proxy Statement"), which was filed with the Securities and Exchange Commission on June 26, 2024. Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., George Migausky and Douglas Hughes were each elected to serve as a member of Immunovant's Board of Directors (the "Board"), until the 2025 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Peter Salzmann, M.D., M.B.A. 99,849,994 31,897,811 6,513,760 George Migausky 98,023,809 33,723,996 6,513,760 Douglas Hughes 97,129,496 34,618,309 6,513,760 Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the fiscal year ending March 31, 2025, by the following votes: Votes For Votes Against Votes Abstain 138,241,628 16,740 3,197 Proposal 3 - Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant's named executive officers
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOVANT, INC. By: /s/ Eva Renee Barnett Eva Renee Barnett Chief Financial Officer Date: August 13, 2024